Clinical Trial Update: Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating intravaginal prasterone for symptoms of vaginal atrophy in women undergoing aromatase inhibitor therapy for breast cancer ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaginal Atrophy in Breast Cancer Patients

Drugs mentioned

• Prasterone (dehydroepiandrosterone (DHEA))

Snippet

Sponsor: EndoCeutics Inc. | Conditions: Vaginal Atrophy in Breast Cancer Patients | Phase 3 | Status: WITHDRAWN